Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03861598 | Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating… | Early Phase 1 | terminated | Mar 4, 2019 | West Virginia University | Due to Covid | COVID-19 / pandemic |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma(FORWARD) | Phase 2 | terminated | Apr 8, 2019 | University of Florida | The study was terminated because the Study Chair/IDE Sponsor and Novocure determined that… | Other (stated, no rule matched) |
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | Phase 2 | withdrawn | Nov 5, 2014 | University of Aarhus | Device for multi coil TMS no longer supported | Other (stated, no rule matched) |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme… | Phase 1 / Phase 2 | terminated | Apr 27, 2010 | M.D. Anderson Cancer Center | Unanticipated Toxicities | Safety / toxicity |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed…(INTACT) | Phase 3 | terminated | Jan 8, 2018 | Diffusion Pharmaceuticals Inc | Business decision on behalf of the Sponsor. | Sponsor / business decision |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor… | Phase 2 | terminated | Feb 24, 2016 | Oslo University Hospital | Slow enrollment as a result of low incidence of MPNST and the COVID-19 pandemic. | COVID-19 / pandemic |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | terminated | Jan 27, 2014 | St. Joseph's Hospital and Medical Center, Phoenix | excessive protocol deviations due to strict nature of diet requirements | Other (stated, no rule matched) |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Phase 2 | terminated | Apr 19, 2016 | RTOG Foundation, Inc. | Treatment now available commercially | Other (stated, no rule matched) |
| NCT01583842 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients… | Early Phase 1 | terminated | Apr 24, 2012 | Miguel Pampaloni | Funding | Funding |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | Phase 1 | withdrawn | Apr 22, 2021 | Jonsson Comprehensive Cancer Center | The P.I. is not prepared to move forward at this thime | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | Phase 3 | terminated | Feb 5, 2018 | AbbVie | The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma… | Other (stated, no rule matched) |
| NCT03980249 | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of… | Early Phase 1 | withdrawn | Jun 10, 2019 | West Virginia University | No funding | Funding |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | Phase 1 | terminated | Sep 14, 2017 | Gary Archer Ph.D. | We are halting enrollment of this study. | Enrollment / accrual |
| NCT02340156 | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | Phase 2 | terminated | Jan 16, 2015 | SynerGene Therapeutics, Inc. | not stated | Not stated |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or… | Phase 1 | terminated | Oct 2, 2014 | Pediatric Brain Tumor Consortium | Data for the primary objectives is complete and the MTD identified in Stratum II. | Other (stated, no rule matched) |
| NCT00592865 | Risk Factors for Adult-Onset Brain Tumors | — | terminated | Jan 14, 2008 | Vanderbilt University Medical Center | not stated | Not stated |
| NCT02580136 | Esthesioneuroblastoma: Outcomes After Treatment(ENB) | — | withdrawn | Oct 20, 2015 | Ricardo L. Carrau, MD | Lack of accrual | Enrollment / accrual |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse… | Phase 2 | terminated | May 2, 2016 | Meyer Children's Hospital IRCCS | Study was terminated due to high heterogeneity of enrolled patients | Enrollment / accrual |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma… | Phase 2 | terminated | Nov 20, 2014 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study was terminated due to lack of clinical activity and not due to safety reasons. | Safety / toxicity |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | Phase 2 | terminated | Sep 20, 2005 | Jean M. Tersak, M.D. | Closed early due to low accrual. | Enrollment / accrual |
| NCT03353896 | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | N/A | withdrawn | Nov 27, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase 1 | withdrawn | Mar 19, 2019 | Matthew Ingham | Study will not proceed, no participants enrolled. | Enrollment / accrual |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | Phase 1 / Phase 2 | terminated | Nov 17, 2015 | Children's Hospital Medical Center, Cincinnati | A competing trial was opened for patient population with combination of ribociclib and everolimus. | Other (stated, no rule matched) |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After… | Phase 3 | terminated | Nov 19, 2013 | Barbara Ann Karmanos Cancer Institute | not stated | Not stated |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03151772 | Bioavailability of Disulfiram and Metformin in Glioblastomas(INSIDE) | Early Phase 1 | terminated | May 12, 2017 | Sahlgrenska University Hospital | Problems with including patients | Other (stated, no rule matched) |
| NCT00698009 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory… | Phase 2 | terminated | Jun 16, 2008 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT01916187 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children… | Phase 1 | withdrawn | Aug 5, 2013 | NCIC Clinical Trials Group | drug company withdrew support following re-examination of benefit-risk assessment for the… | Sponsor / business decision |
| NCT01466855 | A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma(IARB1) | Early Phase 1 | terminated | Nov 8, 2011 | Children's Hospital Medical Center, Cincinnati | Competing studies | Other (stated, no rule matched) |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | Phase 2 | withdrawn | Apr 23, 2018 | John M. Buatti | Not funded | Funding |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System… | Phase 2 | terminated | Oct 31, 2013 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT02919332 | Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With… | — | withdrawn | Sep 29, 2016 | Jonsson Comprehensive Cancer Center | No participants were enrolled | Enrollment / accrual |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in… | Phase 2 | withdrawn | Jan 9, 2017 | Jonsson Comprehensive Cancer Center | Final contract negotiations | Other (stated, no rule matched) |
| NCT00943462 | Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of… | — | withdrawn | Jul 22, 2009 | Centre hospitalier de l'Université de Montréal (CHUM) | No eligible patients could be recruited. | Enrollment / accrual |
| NCT03115138 | Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of…(Bi-GLAM) | N/A | terminated | Apr 14, 2017 | Centre Hospitalier Universitaire, Amiens | investigator choice | Investigator |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First… | Phase 1 | terminated | Oct 16, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding/material support withdrawn | Funding |
| NCT03629964 | Study to Develop Head Stabilizer for Use During Brain Radiation Therapy | N/A | withdrawn | Aug 14, 2018 | University of Chicago | PI left site. | Investigator |
| NCT02116959 | Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in… | Phase 1 | terminated | Apr 17, 2014 | University of California, San Francisco | Low accrual | Enrollment / accrual |
| NCT02855086 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing… | Phase 1 / Phase 2 | terminated | Aug 4, 2016 | Eben Rosenthal | logistics | Other (stated, no rule matched) |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | Phase 1 | terminated | Mar 30, 2020 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT01400672 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | Phase 1 | terminated | Jul 22, 2011 | Masonic Cancer Center, University of Minnesota | Treatment ineffective; Extreme toxicity | Safety / toxicity |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | Phase 2 | terminated | Nov 23, 2011 | Northwestern University | Slow accrual to some cohorts | Enrollment / accrual |
| NCT01349036 | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | Phase 2 | terminated | May 6, 2011 | Daiichi Sankyo | Business Decision | Sponsor / business decision |
| NCT03573986 | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and… | Phase 1 | terminated | Jun 29, 2018 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | Phase 1 / Phase 2 | withdrawn | Jun 4, 2019 | Darell Bigner | Re-submission Planned | Other (stated, no rule matched) |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent…(Toca5) | Phase 2 / Phase 3 | terminated | Apr 10, 2015 | Tocagen Inc. | Sponsor Decision | Sponsor / business decision |
| NCT02764151 | First in Patient Study for PF-06840003 in Malignant Gliomas | Phase 1 | terminated | May 6, 2016 | Pfizer | Sponsor decided to prematurely terminate the study and not to pursue marketing approval for the… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 24, 2021source: clinicaltrials